William Dedmon, DO
Family Medicine · Knoxville, TNNPI 1871054668
Payments from drug & device makers
Across 436 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1K
- Novo Nordisk$988
- GSK$811
- AbbVie$693
- AstraZeneca$605
- Lilly USA, LLC$400
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,219100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 67 | $1,008 |
| Novo Nordisk | 52 | $988 |
| GSK | 47 | $811 |
| AbbVie | 48 | $693 |
| AstraZeneca | 21 | $605 |
| Lilly USA, LLC | 43 | $400 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $391 |
| Johnson & Johnson | 15 | $249 |
| Amgen(2 entities) | 16 | $224 |
| Xeris Pharmaceuticals, Inc. | 11 | $196 |
| Bayer | 11 | $164 |
| Dexcom, Inc. | 7 | $149 |
| Exact Sciences | 9 | $141 |
| Astellas Pharma US Inc | 8 | $141 |
| E.r. Squibb & Sons, L.L.C. | 8 | $118 |
| Phathom Pharmaceuticals, Inc. | 7 | $118 |
| Boehringer Ingelheim | 8 | $115 |
| Novartis | 5 | $110 |
| Shield Therapeutics Inc | 5 | $84 |
| Merck | 4 | $70 |
| Idorsia Pharmaceuticals US Inc | 4 | $67 |
| Alnylam Pharmaceuticals Inc. | 2 | $42 |
| Vanda Pharmaceuticals Inc. | 1 | $39 |
| Boston Scientific | 1 | $39 |
| Sumitomo Pharma America, Inc. | 3 | $36 |
| Axsome Therapeutics, Inc. | 2 | $32 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $31 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Bausch Health US, LLC | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Heartflow, Inc. | 1 | $15 |
| Dynavax Technologies Corporation | 1 | $14 |
| Inogen, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,219 in reported general payments places this provider in the 85th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 49 | $69,857 |
| EliquisApixaban | 50 | $52,066 |
| JardianceEmpagliflozin | 23 | $35,236 |
| TrulicityDulaglutide | 32 | $33,825 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $27,341 |
| XareltoRivaroxaban | 29 | $26,198 |
| JanuviaSitagliptin Phosphate | 13 | $21,244 |
| LinzessLinaclotide | 30 | $20,105 |
| VraylarCariprazine Hcl | 11 | $16,073 |
| MyrbetriqMirabegron | 19 | $13,435 |
| FarxigaDapagliflozin Propanediol | 15 | $9,658 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 41 | $9,353 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $8,187 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $5,248 |
| Novolog FlexpenInsulin Aspart | 17 | $4,168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $988 | $71,27161 claims |
| PfizerEliquis | $1,008 | $52,06650 claims |
| GSKTrelegy Ellipta, Shingrix, Breo Ellipta | $811 | $44,88190 claims |
| AbbVieLinzess, Vraylar, Synthroid | $693 | $37,99563 claims |
| Lilly USA, LLCTrulicity, Humalog | $400 | $37,24443 claims |
| Boehringer IngelheimJardiance | $115 | $35,23623 claims |
| Johnson & JohnsonXarelto | $249 | $26,19829 claims |
| MerckJanuvia | $70 | $21,24413 claims |
| Astellas Pharma US IncMyrbetriq | $141 | $13,43519 claims |
| AstraZenecaFarxiga | $605 | $9,65815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Knoxville
- Rickey ManningKnoxville$8.1M
- Paul WakefieldKnoxville$4.3M
- Jerry PunchKnoxville$2.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Emily HubbsKingsport$2.8M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.